Pharmacy Calls For The FDA To Require Independent Third-Party Testing
Action Follows Assertions That US FDA And Industry Underestimated Metformin Risks
Executive Summary
An online pharmacy that tests medications before dispensing them advocated for regulations requiring independent testing and verification of the chemical content of pharmaceuticals; it also alleged that the US FDA’s testing method for evaluating the carcinogenic risk of metformin needs refinement.
You may also be interested in...
FDA’s Scandal In Waiting?
Headlines about potential carcinogens in the drug supply have been a chronic, low-level challenge for the US FDA’s reputation in recent years. A recent Congressional hearing shows how much tinder is now laid for a potential flare up into a full-on crisis in confidence in the agency.
Metformin Testing Prompts New Finding Of NDMA And Cancer Risk
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
New Testing Prompts New Finding Of NDMA, Cancer Risk In Metformin Products
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.